How Long Should You Cycle CJC/Ipamorelin or Tesamorelin/Ipamorelin?

The common advice you'll hear about CJC-1295 and ipamorelin is to run them for three months, take a month off, and repeat. That protocol is fine as a starting point, but it treats two fundamentally different drugs as if they work the same way on the same system. They don't, and understanding why actually changes how you think about the cycle entirely.

The Full Chain First

Before getting into cycling logic, you need the map of how this system works, because the reason you cycle one compound and potentially not the other lives in the biology.

Your hypothalamus produces something called GHRH, which stands for growth hormone releasing hormone and functions as the brain's primary signal telling the pituitary gland to release growth hormone. CJC-1295 is a synthetic analog of that GHRH signal. It binds to GHRH receptors in the pituitary and tells it to produce more growth hormone, which is exactly what your hypothalamus would do naturally.

Ipamorelin works through an entirely separate pathway. It binds to something called GHS-R1a, which is the receptor for a hunger hormone called ghrelin, and when that receptor is activated in the pituitary, it independently triggers a pulse of growth hormone release. So you have two separate inputs, GHRH and ghrelin, converging on the same output: growth hormone leaving the pituitary.

Growth hormone itself does not build muscle or burn fat directly. What it does is signal your liver to produce something called IGF-1, or insulin-like growth factor 1, which is the molecule that actually drives muscle repair, collagen synthesis, and fat mobilization from storage. Growth hormone is the coach calling the plays. IGF-1 is the players executing them. When you elevate growth hormone through this peptide stack, what you are really doing is raising IGF-1 over time, and that downstream elevation is where the changes you feel are coming from.

Why the Two Receptors Have Different Cycling Rules

Here is where the standard three-months-on, one-month-off protocol gets complicated, because the GHRH receptor and the ghrelin receptor respond to continuous stimulation very differently.

The research on tesamorelin, which is a GHRH analog approved by the FDA and studied extensively in HIV patients with excess visceral fat, gives a clear picture of what happens to the GHRH receptor under prolonged use. In the LIPO-010 trial extension published by Falutz and colleagues in 2008, patients took tesamorelin at 2mg daily for 52 continuous weeks. IGF-1 remained elevated throughout the entire year with no measurable attenuation, meaning the GHRH receptor did not down-regulate or become less sensitive over that time period. The signal stayed just as strong at week 52 as it did at week four.

That evidence suggests the GHRH receptor side of this system, the part that CJC-1295 is targeting, does not require a break to maintain its sensitivity. Continuous stimulation through a GHRH analog appears to be well-tolerated by the receptor itself.

The ghrelin receptor tells a different story. Research on GHS-R1a receptor biology, published in Trends in Endocrinology and Metabolism, shows that continuous agonist exposure causes the receptor to internalize. The mechanism is called agonist-induced internalization, and what it means functionally is that when ipamorelin keeps activating the GHS-R1a receptor repeatedly over an extended period, the receptor gets pulled away from the cell surface through a process involving arrestin-2 recruitment and clathrin-mediated endocytosis. Fewer receptors at the surface means a weaker signal from the same dose of ipamorelin over time.

That is the mechanistic argument for cycling ipamorelin. The receptor physically depletes from the surface under continuous stimulation, and a break period allows recycling back through what the research describes as perinuclear compartments, essentially restoring surface receptor density before you start again.

Now, the important caveat here is that most of this receptor internalization data comes from in vitro studies, meaning cells in a dish, not human clinical trials with ipamorelin specifically. The 90 days on, 30 days off protocol that circulates widely in clinical and optimization communities is extrapolated from this mechanistic reasoning rather than a controlled trial that directly measured ipamorelin's efficacy declining at a specific week. The biology is sound, but the exact timing is informed reasoning, not a proven number.

What gives that reasoning more support is the MK-677 data from Nass and colleagues, published in Annals of Internal Medicine in 2008. MK-677 is an oral ghrelin mimetic, meaning it activates the same GHS-R1a receptor that ipamorelin activates, just in pill form. In that 12-month randomized trial in healthy older adults, daily administration maintained an IGF-1 elevation of 72.9 percent above baseline consistently through the year without obvious attenuation. That data actually complicates the cycling argument somewhat, suggesting that in humans, the functional output from continuous ghrelin receptor stimulation may be more durable than the receptor internalization studies in cell culture would predict.

So the honest picture is this: the receptor biology says ipamorelin should be cycled, the long-term human data on a related compound suggests the signal holds longer than you might expect, and the conservative clinical approach hedges toward cycling ipamorelin regardless, because the downside of taking a break is minimal while the downside of a blunted receptor response is lost efficacy at the same cost.

What Ipamorelin's Selectivity Actually Means for This

Part of why ipamorelin became the standard pairing for CJC-1295 instead of older peptides like GHRP-2 or GHRP-6 is directly about what it does not do. The 1998 study by Raun and colleagues in the European Journal of Endocrinology that first characterized ipamorelin found that it stimulates growth hormone release through GHS-R1a without significantly affecting cortisol, prolactin, or appetite, which were consistent problems with the earlier ghrelin receptor agonists.

GHRP-6 notoriously spiked cortisol and triggered intense hunger signals, which works directly against fat loss goals. Ipamorelin's selectivity for the growth hormone secretagogue receptor without the off-target hormonal effects is what makes it worth stacking in the first place. You get the pulse without the cortisol spike, which means the growth hormone released actually supports fat mobilization rather than working against it through elevated stress hormones.

That selectivity also matters for understanding dose behavior. Because ipamorelin does not significantly drive appetite, the common dose range of 200 to 300 micrograms does not cause the hunger escalation that made GHRP-6 difficult to manage in a caloric deficit. If you are using this stack for fat loss, that distinction is meaningful.

How to Think About the Cycle Structure

The practical conclusion from all of this is that the two compounds in this stack do not necessarily need to be cycled together on the same schedule, even though they are almost always sold and dosed that way.

CJC-1295, based on the GHRH receptor biology and the tesamorelin data, does not appear to require a break period to maintain efficacy. The GHRH receptor does not show the same internalization pattern under continuous stimulation. If you cycled off CJC-1295 while continuing ipamorelin, the ipamorelin pulses would have less baseline growth hormone signal to amplify, which reduces the stack's overall effect.

Ipamorelin, based on GHS-R1a receptor biology, has a mechanistic reason to cycle. The three months on, one month off structure that practitioners commonly recommend gives the receptor time to restore surface density, which should theoretically restore the response quality when you restart.

The simplest practical structure, given that most people use these as a combined stack and most sources supply them together, is the standard 90-day cycle with a 30-day break before resuming. During that break, someone who wants to maintain GHRH receptor stimulation could theoretically continue CJC-1295 alone, though this is not common practice in most clinical settings and moves into territory with even less direct human trial data.

What matters most is understanding that the one-month-off period is primarily about the ghrelin receptor, not the GHRH receptor, and not about some vague concept of giving your body a rest. When you know which receptor you are protecting and why, the protocol is no longer something you follow on faith. It is something you understand.

The deeper insight here is that cycling is not a universal principle. It is receptor-specific. The habit of cycling everything on the same schedule, borrowed loosely from anabolic steroid culture where it has different reasoning entirely, can cause people to either under-cycle compounds that need it or over-cycle ones that do not. These peptides work within your body's own signaling architecture, and that architecture has specific rules. Matching your protocol to those rules is the whole point.

---

References

1. Raun K, Hansen BS, Johansen NL, et al. 1998. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1395, 552-561. Finding: Ipamorelin acts as a selective GHS-R1a agonist to stimulate GH release without significant effects on cortisol, prolactin, or appetite. Source
2. Camina JP, et al. 2004. GHS-R1a constitutive activity and its physiological relevance. Trends in Endocrinology & Metabolism. Finding: GHS-R1a undergoes agonist-induced internalization via arrestin-2 recruitment and clathrin-mediated endocytosis, with recycling through perinuclear compartments. Continuous agonist exposure depletes surface receptor density. Source
3. Nass R, Pezzoli SS, Oliveri MC, et al. 2008. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine, 1499, 601-611. Finding: MK-677 oral ghrelin mimetic administered daily for 12 months maintained IGF-1 elevation of 72.9% above baseline, demonstrating sustained but not necessarily increasing GH axis response with continuous ghrelin receptor agonism. Source
4. Falutz J, et al. 2008. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. LIPO-010 trial extension. Finding: Tesamorelin 2mg daily maintained visceral fat reduction and IGF-1 elevation over 52 weeks of continuous use with no evidence of attenuation, supporting that GHRH receptor does not desensitize with ongoing GHRH analog administration. Source
5. Josh Holyfield established position across multiple videos: "90 days on, 30 days off" for ipamorelin Ghrelin & Growth Hormone: Why Ipamorelin Beats MK-677, ; "GHRH analogs don't need to be cycled" Should You Still Use CJC When Cycling Off Ipamorelin; "three months and then take a month off" What Are CJC-1295 and Ipamorelin

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness